AI-generated analysis. Always verify with the original filing.
Mineralys Therapeutics, Inc. announced fourth quarter and full year 2025 financial results, reporting net loss of $32.2 million for Q4 and $154.7 million for the year, with cash position of $656.6 million as of December 31, 2025. The FDA accepted the NDA for lorundrostat for hypertension treatment, assigning a PDUFA target date of December 22, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 12, 2026, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the q
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued on March 12, 2026 104 Cover Page Interactive Data File (embe
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $24.4K | GAAP |
| Research and Development Expenses | $132.0K | GAAP |
| General and Administrative Expenses | $13.9K | GAAP |
| General and Administrative Expenses | $38.6K | GAAP |
| Total Operating Expenses | $38.3K | GAAP |
| Total Operating Expenses | $170.6K | GAAP |
| Net Loss | $-32.2K | GAAP |
| Net Loss | $-154.7K | GAAP |
| Net Loss per Share | $-0.40 | GAAP |